

# A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

Marie-Claire Wagle<sup>1,2\*</sup>, Daniel Kirouac<sup>1,3</sup>, Christiaan Klijn<sup>4</sup>, Bonnie Liu<sup>2</sup>, Shilpi Mahajan<sup>2</sup>, Melissa Junntila<sup>5</sup>, John Moffat<sup>6</sup>, Mark Merchant<sup>5</sup>, Ling Huw<sup>2</sup>, Matthew Wongchenko<sup>2</sup>, Kwame Okrah<sup>7</sup>, Shrividhya Srinivasan<sup>2</sup>, Zineb Mounir<sup>2</sup>, Teiko Sumiyoshi<sup>2</sup>, Peter M. Haverty<sup>4</sup>, Robert L. Yauch<sup>5</sup>, Yibing Yan<sup>2</sup>, Omar Kabbarah<sup>2</sup>, Garret Hampton<sup>2</sup>, Lukas Amler<sup>2</sup>, Saroja Ramanujan<sup>3</sup>, Mark R. Lackner<sup>2</sup> and Shih-Min A. Huang<sup>2\*</sup>.

<sup>1</sup>These authors contributed equally to this work, Departments of <sup>2</sup>Oncology Biomarker Development, <sup>3</sup>Pre-Clinical and Translational PKPD, <sup>4</sup>Bioinformatics, <sup>5</sup>Translational Oncology, <sup>6</sup>Biochemical and Cellular pharmacology, <sup>7</sup>Biostatistics, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.

\*CORRESPONDENCE: Marie-Claire Wagle: Genentech, 1 DNA Way, South San Francisco, CA 94080, USA, ph: 650-467-3256, marieclw@gene.com. Shih-Min A. Huang (*current affiliation*): Bristol-Myers Squibb, 3551 Lawrenceville Princeton, Lawrence Township, NJ 08648, ph: 650-452-2026, alex.huang1@bms.com.

## Supplementary Materials

## Supplementary Figures

**Supplementary Figure 1:** Expression and correlation of the 10 MAPK genes that constitute MPAS in colorectal, lung and pancreatic patient samples.

**Supplementary Figure 2:** Cross-validation of the E-Net model

**Supplementary Figure 3:** Association of BRAF-mutational status or MPAS with overall survival in patients with mCRC or resectable CRC

**Supplementary Figure 4:** Spearman's Rank Correlation coefficients between EGFR, CDKN1B, and ERBB3 gene expression, and MPAS for HER2+ breast cancer patients.

## Supplementary Tables

**Supplementary Table 1:** MAPK gene expression in melanoma (MEL-JUSO), lung (NCI-H2347) and pancreatic (HUPT4), % inhibition in response to 0.01-1uM cobimetinib treatment for 72 h.

**Supplementary Table 2:** MAPK gene expression, MPAS and cell viability in response to multiple MAPK inhibitors across cell lines from multiple indications.

**Supplementary Table 3:** Standard deviations of either MPAS or actual mean viability across cell lines treated with either MAPK or PI3K/AKT inhibitors.

**Supplementary Table 4:** Short-list of gene clusters identified by the E-Net model as being predictive of MAPK inhibitor (cobimetinib and trametinib) sensitivity.

**Supplementary Table 5:** Genes with expression that correlates with the PHLDA1 gene cluster identified by the E-Net model.

**Supplementary Table 6:** Gene expression, KRAS mutation status and predicted/actual mean viabilities to both trametinib and cobimetinib for cell lines in NSCLC validation set.

**Supplementary Table 7:** Median, maximum and minimum MPAS values for each clinical study.

**Supplementary Table 8:** List of vendors from which melanoma, crc and lung patient samples were procured.

**Supplementary Table 9:** Genes included in the custom MAPK-specific nanostring panel.

**Supplementary Table 10:** Predicted and actual mean viabilities in response to either trametinib or cobimetinib for cell lines included in the E-Net training set.


**Supplementary Table 11:** MPAS and PFS of patients included in the vemurafenib arm of the CoBrim trial.

**Supplementary Table 12:** Individual MAPK gene expression, MPAS and overall survival of patients with metastatic CRC.

**Supplementary Table 13:** Individual MAPK gene expression, MPAS and overall survival of patients with CRC in the adjuvant setting (AVANT).




## Supplementary Figure 1



**Supplementary Figure 1: Expression and correlation of the 10 MAPK genes that constitute MPAS in colorectal, lung and pancreatic patient samples.** (A) Raw gene expression values of each gene are shown and red bars represent median values. Raw counts below 10 were considered below background (geometric mean of the negative controls). (B) Correlation matrices of the genes constituting MPAS across each tissue type.


## Supplementary Figure 2



**Supplementary Figure 2: Cross-validation of the E-Net model**


Predicted mean viabilities of the cell lines used to train the model were correlated with experimentally derived mean viabilities to both trametinib and cobimetinib treatment.

### Supplementary Figure 3



**Supplementary Figure 3: Association of BRAF-mutational status or MPAS with overall survival in patients with mCRC or resectable CRC**  
 Kaplan-Meier curves for overall survival were plotted according to (a) BRAF-mutational status in mCRC and resectable CRC; (b) MPAS high vs low in mCRC in KRAS-mutant patients and in KRAS/BRAF-wild-type patients; (c) MPAS high vs low in resectable CRC in KRAS-mutant patients and in KRAS/BRAF-wild-type patients.(d) Hazard ratios based on individual MAPK gene expression.

## Supplementary Figure 4



Supplementary Figure 4: Spearman's Rank Correlation coefficients between EGFR, CDKN1B, and ERBB3 gene expression, and MPAS for HER2+ breast cancer patients.

**Supplementary Table 1**

NCI-H2347		cobimetinib mM			
<b>MAPK genes included in MPAS</b>					
Gene name	0.01	0.1	0.3	1	
DUSP4	84.009818	35.643594	27.190967	19.840943	
DUSP6	47.248463	3.6312725	2.0102699	1.6448766	
SPRY2	97.973703	69.697768	57.526811	56.651999	
SPRY4	53.397032	11.117733	8.6011996	8.1301907	
ETV4	75.287801	63.019759	60.80756	52.484966	
ETV5	91.32767	50.136426	39.706065	38.61466	
EPHA2	63.371252	22.808825	16.801277	15.679199	
EPHA4	56.282802	26.257878	24.385499	27.378468	
CCND1	79.840366	55.029664	49.55298	48.757693	
PHLDA1	59.920227	16.641753	11.959699	10.954393	
<b>MAPK target genes not included in MPAS</b>					
INPP5F	95.098361	91.2922	93.438092	92.598326	
MAP2K3	94.577957	79.448325	83.714139	74.641885	
TRIB2	63.343938	50.281607	36.361494	47.071992	
ETV1	86.091355	53.854333	55.643203	53.681912	
HUP-T4		cobimetinib mM			
<b>MAPK genes included in MPAS</b>					
Gene name	0.01	0.1	0.3	1	
DUSP4	76.336449	17.050127	11.564996	6.7969414	
DUSP6	49.301246	4.6825306	2.1822457	2.4345015	
SPRY2	69.159009	22.820941	18.803954	13.227513	
SPRY4	49.284206	16.32246	6.9701948	6.4538841	
ETV4	56.787565	25.751295	11.19171	5.1813472	
ETV5	59.962687	25.932836	20.149254	7.4626866	
EPHA2	73.96657	40.20447	33.604622	32.776262	
EPHA4	67.624009	41.396946	35.555819	35.27643	
CCND1	85.876056	51.258585	46.229946	46.347097	
PHLDA1	41.983977	6.9209501	4.8211525	4.7895848	
<b>MAPK target genes not included in MPAS</b>					
INPP5F	98.385829	95.278025	83.795399	86.468214	
MAP2K3	58.541731	60.330432	27.371702	27.879488	
TRIB2	104.56906	100.09922	97.721914	96.892113	
ETV1	77.323287	28.507356	32.956584	28.7047	
MEL-JUSO		cobimetinib mM			
<b>MAPK genes included in MPAS</b>					
Gene name	0.01	0.1	0.3	1	
DUSP4	93.430208	66.927549	40.285665	28.729698	
DUSP6	57.927467	22.318912	7.1517999	2.7265561	
SPRY2	100.74749	59.635738	27.617305	10.650026	
SPRY4	58.016714	12.803481	4.1164814	2.3020591	
ETV4	89.913793	55.901254	43.510972	65.23511	
ETV5	139.99269	77.657592	45.770144	40.931847	
EPHA2	64.568901	41.565031	26.457866	24.064136	
EPHA4	75.691057	64.444444	55.98916	55.691057	
CCND1	83.156671	47.593063	27.755948	22.979558	
PHLDA1	75.101762	59.373121	48.82742	40.521648	
<b>MAPK target genes not included in MPAS</b>					
INPP5F	83.926748	58.14958	43.547277	39.593179	
MAP2K3	60.836602	56.536133	31.639033	32.63122	
TRIB2	120.78999	103.25927	68.948157	53.587973	
ETV1	110.8749	87.382614	65.637116	63.080469	

**Supplementary Table 1: MAPK gene expression in melanoma (MEL-JUSO), lung (NCI-H2347) and pancreatic (HUPT4), % inhibition in response to 0.01-1uM cobimetinib treatment for 72 h.**























**Supplementary Table 3**

cell line indication	MPAS (STD)	Mean Viability (STD)					
		GDC0068	GDC0941	Cobimetinib	PD0325901	GDC0623	Vemurafenib
		(AKT)	(PI3K)	(MEK)	(MEK)	(MEK)	(BRAF)
Breast	0.454	0.110	0.082	0.101	0.153	0.108	0.041
Lung	0.478	0.083	0.075	0.138	0.199	0.121	0.043
Colorectal	0.254	0.078	0.078	0.160	0.195	0.116	0.100
Pancreatic	0.162	0.060	0.055	0.102	0.140	0.078	0.043
Melanoma	0.174	0.078	0.074	0.139	0.164	0.071	0.115

**Supplementary Table 3:** Standard deviations of either MPAS or actual mean viability across cell lines treated with either MAPK or PI3K/AKT inhibitors.

**Supplementary Table 4**

Cobimetinib	Gene name	chromosome location	shortlist coefficient
	THG1L	chr5:157158323-157166772	-0.0148
	LINC00460	chr13:107028911-107030140	-0.0114
	TIMP1	chrX:47441690-47446190	-0.00705
	FERMT1	chr20:6055492-6104191	-0.00589
	*PHLDA1	chr12:76419227-76425556	-0.00343
	S100A4	chr1:153516095-153518282	-0.00237
	PLEK2	chr14:67853700-67878828	-0.000503
Trametinib	Gene name	chromosome location	shortlist coefficient
	THG1L	chr5:157158323-157166772	-0.025143138
	*PHLDA1	chr12:76419227-76425556	-0.018512537
	PLEK2	chr14:67853700-67878828	-0.012443006
	TIMP1	chrX:47441690-47446190	-0.00995946
	LINC00460	chr13:107028911-107030140	-0.009487112
	FERMT1	chr20:6055492-6104191	-0.004975383
	S100A4	chr1:153516095-153518282	-0.003213673

**Supplementary Table 4: Short-list of gene clusters identified by the E-Net model as being predictive of MAPK inhibitor (cobimetinib and trametinib) sensitivity. \*PHLDA group also included SPRY2, SPRY4, DUSP6, CCND1 and EPHA2**

**Supplementary Table 5**

Gene	Correlation coefficient
<i>PHLDA1</i>	1
FOSL1	0.687
<i>EPHA2</i>	0.651
PXN	0.633
PHLDA2	0.63
<i>CCND1</i>	0.62
CD97	0.617
ADORA2B	0.611
IER3	0.611
ITGA2	0.61
S100A11	0.61
LOC100216001	0.609
LOC100294307	0.605
SPATS2L	0.605
LOC100653318	0.605
LOC100652851	0.604
C1orf170	0.603
PLAUR	0.592
ANXA2	0.59
LOC100506484	0.589
<i>SPRY4</i>	0.586
YAP1	0.585
TIMP1	0.584
ZFP36L1	0.584
SPRED1	0.581
AHNAK	0.58
DNMBP	0.58
RHOC	0.579
PLEKHG1	0.578
<i>DUSP6</i>	0.577
DCBLD2	0.574
LIF	0.572
RPSAP52	0.57

TNFRSF12A		0.569
FXYD5		0.568
TGFBR2		0.567
NTSE		0.567
FHL2		0.566
ANXA1		0.565
STEAP1		0.563
HRH1		0.561
TRIP10		0.556
CMTM7		0.555
CLIC1		0.554
RIN1		0.554
ELK3		0.554
LOC100506377		0.553
<b>SPRY2</b>		0.553
SP100		0.552
CDCP1		0.549
RALB		0.549
MYOF		0.549
CSF2		0.548
SMAGP		0.548
TNFRSF10B		0.547
SMAD3		0.545
LOC541471		0.544
TMSB10		0.544
LOC100653218		0.544
EMP1		0.544
CNN2		0.544
LOC100287314		0.544
TMBIM1		0.541
LOC100506649		0.54
S100A16		0.54
NPAS2		0.539
LOC100129940		0.538

LMNA		0.538
S100A10		0.537
CAPN2		0.537
ADAMTSL5		0.536
AREGB		0.535
SH3TC2		0.535
ERRFI1		0.532
LINC00460		0.53
TUBA1C		0.529
ITGA3		0.528
PLAU		0.527
TM4SF1		0.526
MIR221		0.526
MIR614		0.525
CD9		0.524
MYEOV		0.522
RNF149		0.521
CIB1		0.521
LOC100652804		0.52
LOC100653288		0.52
HMGA2		0.519
CTSB		0.518
S100A6		0.517
GPRC5A		0.517
RUNX1		0.517
CAV2		0.516
GSTO1		0.516
PTPN12		0.515
CATSPER1		0.515
LOC100508196		0.514
SERTAD1		0.513
ITGA6		0.513
C10orf55		0.511
CASP8		0.511

F2RL1		0.511
ITGB5		0.51
PLIN3		0.51
BAG3		0.51
EHBP1L1		0.509
IRAK2		0.508
LOC389602		0.508
SOX9		0.507
REST		0.507
ANXA2P2		0.506
SFXN3		0.506
SLC16A3		0.505
VPS37B		0.505
AREG		0.504
EPHB4		0.503
LRRC8E		0.503
ARL14		0.503
FERMT1		0.502
IGF2BP2		0.502
ANXA2P1		0.502
RPS6KA4		0.502

**Supplementary Table 5: Genes with expression that correlates with the PHLDA1 gene cluster identified by the E-Net model.**

\*Genes in larger bold italic font are known MAPK target genes and are included in MPAS



## Supplementary Table 7

Study	Figure ID	Median	Max	Min
COBRIM	3	0.08	1.33	-2.26
mCRC	4B	-0.13	4.09	-1.90
AVANT	4C	1.10	2.96	-1.27
TCGA (Adrenal)	5A	-0.62	2.55	-4.69
METABRIC (HER2+)	5Civ	0.14	4.51	-4.47

Supplementary Table 7: Median, maximum and minimum MPAS values for each clinical study.

## Supplementary Table 8

	Vendor
Melanoma (n=50)	Folio Biosciences, LLC Asterand Bioscience ProteoGenex Inc. The MT group Inc.
CRC (n=50)	The MT group Inc. Tristar Technology ventures
Lung (n=100)	Tristar Technology ventures The MT group Inc. Cureline, Inc ClinPath advisors

Supplementary Table 8: List of vendors from which melanoma, crc and lung patient samples were procured.

## Supplementary Table 9

Gene name	Role on panel
DUSP6	MAPK target
SPRY2	MAPK target
CCND1	MAPK target
DUSP4	MAPK target
SPRY4	MAPK target
ETV4	MAPK target
ETV5	MAPK target
EPHA2	MAPK target
EPHA4	MAPK target
PHLDA1	MAPK target
CLTC	HK genes
GUSB	HK genes
HPRT1	HK genes
PGK1	HK genes
SDHA	HK genes

Supplementary Table 9: Genes included in the custom MAPK-specific nanostring panel.

**Supplementary Table 10**

Cell line name	primary tissue	predicted values of mean viability		actual mean viability	
		cobimetinib	trametinib	cobimetinib	trametinib
LS-174T	Colon	0.673	0.533	0.691	0.545
SW 48	Colon	0.650	0.535	0.615	0.421
OUMS-23	Colon	0.780	0.748	0.826	0.862
COLO 201	Colon	0.527	0.407	0.279	0.172
COLO 320	Colon	0.854	0.849	0.934	1.000
DLD-1	Colon	0.706	0.587	0.801	0.682
CL-34	Colon	0.636	0.520	0.623	0.532
SW 1463	Colon	0.642	0.527	0.633	0.510
LS-174T	Colon	0.672	0.535	0.593	0.429
SW 480	Colon	0.664	0.543	0.626	0.490
SK-CO-1	Colon	0.626	0.496	0.492	0.325
DLD-1	Colon	0.665	0.558	0.750	0.608
RKO	Colon	0.614	0.514	0.479	0.442
COLO 741	Colon	0.764	0.690	0.671	0.536
Caco-2	Colon	0.779	0.675	0.865	0.748
LS-174T	Colon	0.670	0.537	0.754	0.557
HCT 116	Colon	0.677	0.530	0.892	0.836
HT-29	Colon	0.605	0.504	0.374	0.305
LoVo	Colon	0.670	0.522	0.613	0.441
COLO 201	Colon	0.556	0.462	0.360	0.302
HCA-7	Colon	0.709	0.592	0.694	0.465
CL-11	Colon	0.646	0.480	0.528	0.372
SW 620	Colon	0.643	0.525	0.627	0.424
KM-12	Colon	0.667	0.547	0.859	0.802
HT-55	Colon	0.691	0.572	0.636	0.573
HT-29	Colon	0.617	0.508	0.384	0.244
T84	Colon	0.655	0.506	0.745	0.560
SW 403	Colon	0.639	0.530	0.685	0.519
SW 948	Colon	0.641	0.501	0.651	0.556
C170	Colon	0.661	0.529	0.623	0.460
COLO 678	Colon	0.699	0.606	0.726	0.647
CX-1	Colon	0.597	0.453	0.509	0.293
MDST8	Colon	0.675	0.591	0.723	0.642
Caco-2	Colon	0.777	0.683	0.770	0.696
COLO 320	Colon	0.869	0.854	0.962	1.001
HCC1263	Colon	0.710	0.627	0.746	0.651
SNU-C1	Colon	0.720	0.618	0.729	0.593
RKO	Colon	0.644	0.532	0.569	0.450
HCT 116	Colon	0.666	0.523	0.512	0.277
HT-115	Colon	0.714	0.576	0.678	0.557
GP2d	Colon	0.736	0.658	0.731	0.623
CaR-1	Colon	0.709	0.608	0.736	0.675
CW-2	Colon	0.718	0.621	0.845	0.784
RCM-1	Colon	0.651	0.532	0.732	0.575
NCI-H358	Lung	0.716	0.606	0.665	0.491
NCI-H292	Lung	0.734	0.654	0.503	0.354
NCI-H522	Lung	0.825	0.812	0.823	0.854
NCI-H650	Lung	0.664	0.543	0.742	0.603
NCI-H23	Lung	0.728	0.643	0.563	0.388
NCI-H520	Lung	0.814	0.747	0.861	0.792
NCI-H647	Lung	0.752	0.682	1.021	0.962
NCI-H1437	Lung	0.697	0.601	0.529	0.389
HCC827	Lung	0.728	0.604	0.713	0.567
ABC-1	Lung	0.781	0.716	0.842	0.764
RERF-LC-KJ	Lung	0.757	0.684	0.770	0.748
Calu-3	Lung	0.724	0.619	0.806	0.772
NCI-H460	Lung	0.713	0.611	0.719	0.629
NCI-H1299	Lung	0.759	0.654	0.655	0.553
NCI-H226	Lung	0.755	0.701	0.756	0.689
NCI-H1944	Lung	0.741	0.656	0.722	0.614
NCI-H2106	Lung	0.892	0.892	0.991	0.994

SW 1573	Lung	0.718	0.609	0.813	0.740	
SK-MES-1	Lung	0.702	0.601	0.682	0.526	
HCC-15	Lung	0.671	0.548	0.597	0.494	
NCI-H2122	Lung	0.696	0.570	0.636	0.439	
NCI-H441	Lung	0.734	0.625	0.793	0.727	
A549	Lung	0.688	0.573	0.541	0.400	
NCI-H1703	Lung	0.765	0.740	0.866	0.935	
NCI-H1666	Lung	0.662	0.548	0.637	0.559	
NCI-H82	Lung	0.908	0.919	0.944	1.037	
LXFL529	Lung	0.829	0.756	0.863	0.730	
NCI-H2171	Lung	0.911	0.908	0.948	0.997	
NCI-N417	Lung	0.887	0.860	1.025	1.010	
NCI-H2405	Lung	0.743	0.670	0.360	0.296	
NCI-H661	Lung	0.754	0.684	0.753	0.728	
NCI-H1155	Lung	0.844	0.827	1.013	1.029	
RERF-LC-MS	Lung	0.710	0.616	0.658	0.534	
HOP-62	Lung	0.704	0.618	0.761	0.658	
NCI-H1838	Lung	0.737	0.646	0.856	0.860	
NCI-H2009	Lung	0.724	0.619	0.575	0.472	
VMRC-LCD	Lung	0.849	0.821	0.892	0.943	
H322T	Lung	0.775	0.677	0.724	0.610	
RERF-LC-OK	Lung	0.739	0.674	0.835	0.759	
NCI-H727	Lung	0.681	0.594	0.479	0.331	
NCI-H1651	Lung	0.818	0.766	0.890	0.837	
KNS-62	Lung	0.710	0.588	0.644	0.488	
HOP-92	Lung	0.701	0.590	0.633	0.450	
NCI-H446	Lung	0.855	0.834	0.873	0.783	
NCI-H322T	Lung	0.737	0.609	0.759	0.583	
HCC4006	Lung	0.747	0.655	0.783	0.653	
SU-DHL-10	Lung	0.787	0.704	0.925	0.848	
NCI-H1355	Lung	0.727	0.641	0.739	0.740	
NCI-H187	Lung	0.921	0.938	1.032	1.030	
NCI-H196	Lung	0.817	0.757	0.916	0.842	
NCI-H2170	Lung	0.822	0.804	1.054	1.106	
NCI-H146	Lung	0.899	0.907	0.913	0.934	
NCI-H889	Lung	0.881	0.886	0.926	0.956	
ChaGo-K-1	Lung	0.818	0.796	0.917	0.938	
NCI-H2110	Lung	0.740	0.649	0.892	0.823	
HCC515	Lung	0.684	0.555	0.698	0.618	
HCC1171	Lung	0.734	0.634	0.680	0.575	
HCC4017	Lung	0.708	0.578	0.714	0.604	
NCI-H2228	Lung	0.716	0.611	0.842	0.726	
DV-90	Lung	0.693	0.595	0.621	0.513	
HCC44	Lung	0.686	0.569	0.607	0.421	
HCC78	Lung	0.734	0.646	0.794	0.748	
LCLC-103H	Lung	0.776	0.726	0.829	0.955	
BEN	Lung	0.832	0.773	0.917	0.849	
CAL-12T	Lung	0.677	0.550	0.628	0.548	
EPLC-272H	Lung	0.744	0.658	0.783	0.726	
LCLC-97TM1	Lung	0.688	0.557	0.702	0.488	
LXF-289	Lung	0.752	0.643	0.687	0.576	
SCLC-21H	Lung	0.917	0.925	0.912	0.985	
SCLC-22H	Lung	0.874	0.873	0.926	0.972	
NCI-H1339	Lung	0.754	0.678	0.814	0.703	
NCI-H1930	Lung	0.942	0.968	1.081	1.137	
NCI-H23	Lung	0.757	0.663	0.778	0.645	
HCC2885	Lung	0.763	0.666	0.834	0.740	
UMC-11	Lung	0.851	0.873	0.882	0.937	
COR-L26	Lung	0.739	0.646	0.753	0.602	
COR-L279	Lung	0.882	0.869	0.979	1.019	
COR-L47	Lung	0.901	0.916	1.003	1.028	
COR-L88	Lung	0.894	0.903	0.915	0.925	
MOR	Lung	0.751	0.690	0.876	0.837	

HCC2279	Lung	0.755	0.675	0.842	0.817	
NCI-H1581	Lung	0.814	0.810	0.740	0.681	
NCI-H1869	Lung	0.741	0.656	0.751	0.701	
NCI-H2023	Lung	0.759	0.674	0.742	0.698	
NCI-H2135	Lung	0.680	0.513	0.588	0.308	
NCI-H2347	Lung	0.699	0.556	0.627	0.463	
HCC364	Lung	0.658	0.500	0.380	0.146	
HCC4011	Lung	0.764	0.659	0.836	0.757	
HCC2302	Lung	0.764	0.699	0.796	0.740	
DMS 273	Lung	0.840	0.820	0.904	0.990	
HCC4019	Lung	0.749	0.677	0.755	0.659	
HCC1534	Lung	0.797	0.732	0.882	0.780	
NCI-H2461	Lung	0.776	0.725	0.780	0.699	
NCI-H2052	Lung	0.745	0.700	0.864	1.030	
HCC461	Lung	0.714	0.612	0.735	0.583	
NCI-H2373	Lung	0.737	0.677	0.759	0.702	
NCI-H2452	Lung	0.754	0.671	0.835	0.748	
NCI-H28	Lung	0.780	0.732	0.925	0.900	
NCI-H2595	Lung	0.783	0.745	0.800	0.814	
NCI-H2369	Lung	0.774	0.703	0.855	0.823	
NCI-H2803	Lung	0.779	0.735	0.781	0.721	
NCI-H2804	Lung	0.781	0.744	0.866	0.876	
NCI-H2722	Lung	0.779	0.707	0.836	0.769	
NCI-H2810	Lung	0.734	0.656	0.635	0.533	
NCI-H2731	Lung	0.747	0.672	0.853	0.816	
HPAC	Pancreas	0.610	0.491	0.540	0.398	
BxPC-3	Pancreas	0.674	0.560	0.742	0.632	
SW 1990	Pancreas	0.675	0.575	0.708	0.621	
MIA Paca-2	Pancreas	0.697	0.595	0.584	0.447	
HUP-T3	Pancreas	0.708	0.581	0.672	0.476	
PANC-1	Pancreas	0.725	0.624	0.786	0.725	
PSN1	Pancreas	0.622	0.478	0.422	0.194	
KP4	Pancreas	0.696	0.599	0.697	0.625	
SU.86.86	Pancreas	0.723	0.615	0.725	0.627	
Capan-2	Pancreas	0.648	0.524	0.607	0.462	
CFPAC-1	Pancreas	0.694	0.591	0.707	0.690	
Capan-1	Pancreas	0.693	0.568	0.795	0.669	
HPAF-II	Pancreas	0.623	0.455	0.553	0.343	
AsPC-1	Pancreas	0.603	0.458	0.611	0.479	
Hs 766T	Pancreas	0.674	0.559	0.512	0.344	
Panc 04.03	Pancreas	0.649	0.537	0.603	0.460	
Panc 03.27	Pancreas	0.663	0.543	0.660	0.523	
Panc 05.04	Pancreas	0.649	0.524	0.563	0.465	
Panc 02.03	Pancreas	0.607	0.464	0.447	0.257	
PA-TU-8988T	Pancreas	0.738	0.655	0.713	0.708	
PA-TU-8902	Pancreas	0.643	0.504	0.638	0.446	
HUP-T4	Pancreas	0.696	0.601	0.597	0.480	
KLM-1	Pancreas	0.725	0.624	0.782	0.627	
KP-3	Pancreas	0.722	0.636	0.811	0.772	
PK-45H	Pancreas	0.702	0.601	0.506	0.366	
PK-59	Pancreas	0.645	0.516	0.678	0.552	
PK-8	Pancreas	0.661	0.536	0.593	0.399	
QGP-1	Pancreas	0.804	0.743	0.755	0.706	
DAN-G	Pancreas	0.713	0.627	0.821	0.678	
KCI-MOH1	Pancreas	0.623	0.501	0.563	0.394	
PK-1	Pancreas	0.647	0.530	0.579	0.441	
PK-45P	Pancreas	0.675	0.568	0.632	0.501	
PA-TU-8988S	Pancreas	0.682	0.568	0.668	0.512	
SUIT-2	Pancreas	0.674	0.557	0.580	0.362	
TCC-PAN2	Pancreas	0.661	0.530	0.675	0.601	
YAPC	Pancreas	0.672	0.567	0.780	0.718	

Supplementary Table 10: Predicted and actual mean viabilities in response to either trametinib or cobimetinib for cell lines included in the E-Net training set .

**Supplementary Table 11**

CC/IM	MPAS	PFS (Months)
Cell Cycle	0.33	2.76
Cell Cycle	-0.16	3.32
Cell Cycle	0.05	7.72
Cell Cycle	0.16	1.84
Cell Cycle	-0.25	2.99
Cell Cycle	-0.95	0.10
Cell Cycle	0.05	6.54
Cell Cycle	0.45	3.45
Cell Cycle	1.33	7.16
Cell Cycle	0.15	3.45
Cell Cycle	0.80	5.52
Cell Cycle	0.64	3.48
Cell Cycle	0.24	11.07
Cell Cycle	0.33	5.55
Cell Cycle	0.45	5.55
Cell Cycle	0.36	16.59
Cell Cycle	1.14	12.91
Cell Cycle	0.25	2.76
Cell Cycle	0.00	7.46
Cell Cycle	0.74	15.18
Cell Cycle	1.21	12.98
Cell Cycle	0.15	0.03
Cell Cycle	0.78	11.04
Cell Cycle	0.08	3.65
Cell Cycle	0.52	2.83
Cell Cycle	0.54	3.52
Cell Cycle	0.19	2.04
Cell Cycle	0.51	3.94
Cell Cycle	-0.23	5.29
Cell Cycle	1.30	14.65
Cell Cycle	0.34	14.98
Cell Cycle	-0.42	7.39
Cell Cycle	0.34	2.76
Cell Cycle	0.12	13.67
Cell Cycle	-0.26	5.59
Cell Cycle	0.63	9.46
Cell Cycle	-0.01	9.13
Cell Cycle	0.57	1.74
Cell Cycle	0.66	3.48
Cell Cycle	-0.32	1.87
Cell Cycle	0.96	5.13
Cell Cycle	-0.29	3.58
Cell Cycle	-0.05	1.84
Cell Cycle	0.49	5.52
Cell Cycle	0.64	3.58
Cell Cycle	0.26	7.62
Cell Cycle	-0.06	7.69
Immune	0.89	16.43
Immune	-0.11	5.55
Immune	-0.87	4.50
Immune	-0.34	11.10
Immune	-0.35	15.01
Immune	-0.26	18.63
Immune	-0.49	7.82
Immune	-0.06	1.87
Immune	-0.09	5.78
Immune	0.18	18.40
Immune	0.54	18.60
Immune	-0.66	18.17
Immune	-0.23	3.81
Immune	0.11	16.85

Immune	-0.43	18.37
Immune	-0.15	16.46
Immune	0.02	11.50
Immune	-0.69	3.71
Immune	-0.59	15.70
Immune	0.79	7.23
Immune	0.50	5.75
Immune	0.13	16.85
Immune	-0.08	7.33
Immune	-0.32	7.69
Immune	-1.87	6.51
Immune	0.28	13.86
Immune	-0.12	6.21
Immune	0.05	9.13
Immune	0.18	3.42
Immune	0.16	0.03
Immune	0.20	13.04
Immune	-0.20	5.59
Immune	0.00	13.14
Immune	0.14	13.80
Immune	-0.15	12.88
Immune	-0.58	8.97
Immune	-0.29	1.91
Immune	-0.59	5.55
Immune	0.42	7.46
Immune	-0.64	1.71
Immune	-0.52	3.48
Immune	-0.57	1.77
Immune	-0.55	13.14
Immune	0.43	13.04
Immune	0.12	13.01
Immune	-1.58	1.84
Immune	-0.78	9.33
Immune	-0.12	7.00
Immune	-0.01	4.11
Immune	0.54	1.87
Immune	-2.26	7.29
Immune	0.08	2.20

**Supplementary Table 11: MPAS and PFS of patients included in the vemurafenib arm of the CoBrim trial.**



0.53	0.21	0.06	-0.25	0.24	0.74	0.26	-0.15	0.26	0.17	0.65	MND	MUT	'Censored'	7.25
0.26	0.99	0.91	1.46	1.53	-0.60	-0.25	0.50	-0.53	0.50	1.51	MND	MUT	'Death'	0.17
1.11	1.40	1.65	1.58	1.12	1.10	1.61	2.65	2.26	1.98	5.20	MND	MUT	'Death'	2.5
-1.54	-0.95	-1.81	-1.66	-0.06	-1.75	-1.64	-0.45	-1.26	-1.54	-4.00	MND	MUT	'Death'	1.25
0.66	0.72	-0.19	-0.30	1.03	0.06	-0.32	0.61	0.49	0.03	0.89	MND	MUT	'Censored'	2.67
0.12	0.55	0.66	0.62	-0.20	0.18	0.25	0.23	-0.69	-0.18	0.48	MUT	MND	'Death'	9
0.31	2.26	1.96	1.62	1.19	1.35	2.82	0.64	2.42	2.51	5.40	MND	MUT	'Death'	0.08
1.49	-0.30	0.69	0.02	0.40	0.71	0.88	-0.05	0.73	0.52	1.60	MND	MND	'Censored'	1.67
0.92	0.20	0.37	0.43	0.59	0.36	1.11	0.58	0.06	0.46	1.60	MND	MND	'Death'	0.42
-1.19	-1.04	-1.31	-0.47	-1.50	-0.83	-0.75	-1.71	-1.74	-1.17	-3.70	MND	MND	'Death'	1
0.72	-0.07	0.38	0.21	0.24	0.69	0.47	-0.20	0.44	0.38	1.03	MND	MND	'Death'	5.5
0.71	1.86	0.88	1.65	0.37	0.55	1.40	0.80	0.66	1.38	3.24	MUT	MND	'Death'	0.83
0.58	0.30	1.34	0.69	0.53	1.08	1.42	0.67	1.06	1.07	2.76	MND	MND	'Death'	1.08
0.26	0.12	0.12	0.77	-0.11	-0.13	0.25	0.04	-0.25	0.44	0.48	MND	MND	'Death'	2.25
1.48	2.24	1.97	2.02	2.34	0.25	1.75	2.25	0.92	0.93	5.11	MND	MUT	'Death'	0.08
-1.47	-0.71	-1.02	-1.53	-1.24	-0.79	-0.44	-2.18	0.15	-0.72	-3.15	MND	MUT	'Censored'	5.25
0.98	0.55	1.25	1.33	1.25	1.12	1.50	1.21	0.80	1.53	3.64	MND	MND	'Censored'	0.67
0.08	1.47	0.37	0.49	1.16	-0.46	0.75	0.12	-0.13	-0.11	1.19	MUT	MND	'Death'	2.83
0.31	-0.36	0.06	-0.91	-0.81	0.40	-0.41	1.35	0.35	0.36	0.11	MND	MUT	'Death'	1.34
-0.90	0.36	-1.00	-0.20	0.99	-2.49	-0.08	-1.19	-1.34	-1.29	-2.26	MUT	MND	'Death'	1.25
-0.33	-0.71	0.05	-0.23	-0.60	0.32	-1.09	-0.92	-0.41	-0.64	-1.44	<undefined>	<undefined>	'Censored'	13.08
0.07	0.15	-0.23	-0.34	-0.97	0.05	0.04	-0.29	-0.72	-0.12	-0.75	MND	MND	'Death'	1.34
0.34	-0.43	0.12	0.49	0.04	0.29	-0.64	0.20	0.19	0.34	0.29	MND	MND	'Death'	6.34
0.53	1.09	0.52	-0.61	0.31	-1.34	0.43	1.67	-0.07	0.27	0.88	MND	MUT	'Death'	1.92
-0.42	-0.41	-0.36	-0.35	0.26	-0.47	0.20	-0.10	-1.35	-0.85	-1.23	MND	MUT	'Death'	1.59
-0.60	-0.46	-0.26	-0.45	-0.86	-0.20	-0.13	0.12	-1.01	0.31	-1.12	<undefined>	<undefined>	'Death'	2.92
0.86	0.66	0.67	0.81	0.45	0.69	0.57	0.13	1.28	0.84	2.20	<undefined>	<undefined>	'Censored'	3.25
1.13	1.63	1.25	0.90	0.77	1.10	0.81	0.52	1.41	1.14	3.37	<undefined>	<undefined>	'Death'	1.08
-0.21	-0.60	-0.71	-1.15	-0.18	-0.99	-0.44	-0.81	-0.90	-0.33	-2.00	<undefined>	<undefined>	'Death'	6.25

Supplementary Table 12: Individual MAPK gene expression, MPAS and overall survival of patients with metastatic CRC.

**Supplementary Table 13**

Treatment	individual MAPK gene expression						MPAS	CSDIED	TTMDIED	mutation status	
	DUSP6	SPRY2	CCND1	ETV4	ETV5	EPHA4				BRAF	KRAS
FOLFOX-4	2.99	3.11	3.12	2.73	2.25	1.59	0.70	0	72.38	WT	WT
FOLFOX-4	2.86	2.84	2.66	2.50	2.32	2.31	0.21	0	72.54	MUT	NA
FOLFOX-4	3.01	2.76	3.54	2.86	2.05	1.99	1.10	0	76.25	WT	NA
FOLFOX-4	3.29	3.01	3.19	2.75	2.10	2.15	1.50	1	61.11	WT	WT
FOLFOX-4	3.09	2.63	3.21	2.21	2.06	2.68	0.60	0	58.84	WT	MUT
FOLFOX-4	2.90	2.67	3.13	2.23	2.08	2.42	0.04	1	58.87	WT	WT
FOLFOX-4	2.90	2.85	3.04	2.82	2.15	1.57	-0.02	0	60.78	WT	WT
FOLFOX-4	3.35	3.00	3.25	2.47	2.12	2.27	1.49	0	48.13	WT	MUT
FOLFOX-4	2.82	2.66	2.99	2.30	2.00	1.85	-1.05	1	56.34	WT	NA
FOLFOX-4	3.13	2.69	3.32	2.61	1.92	1.91	0.21	0	66.23	WT	MUT
FOLFOX-4	3.18	2.88	3.18	2.77	2.08	1.72	0.59	0	81.02	WT	MUT
FOLFOX-4	2.96	2.95	3.52	2.67	1.89	1.95	0.71	0	75.63	WT	WT
FOLFOX-4	3.17	3.15	3.36	3.01	1.92	2.22	1.83	0	61.17	WT	MUT
FOLFOX-4	3.14	2.53	3.33	2.34	2.31	2.29	0.86	0	76.62	WT	MUT
FOLFOX-4	2.72	2.37	3.18	2.06	1.93	2.09	-1.46	0	68.9	WT	NA
FOLFOX-4	2.74	2.49	2.85	1.84	1.72	1.96	-2.55	1	79.34	WT	MUT
FOLFOX-4	3.47	2.72	3.31	2.66	2.13	2.42	1.76	0	76.25	WT	MUT
FOLFOX-4	3.18	2.77	3.42	2.67	2.19	2.71	2.09	0	66.99	WT	WT
FOLFOX-4	3.10	3.02	2.99	2.95	2.03	1.88	0.72	0	78.49	WT	MUT
FOLFOX-4	2.70	2.81	3.02	2.14	1.89	2.16	-0.97	0	78.16	WT	WT
FOLFOX-4	2.87	2.67	3.15	2.72	1.90	2.52	0.38	0	63.18	WT	NA
FOLFOX-4	2.61	2.81	2.82	2.64	1.86	1.71	-1.40	0	67.25	WT	MUT
FOLFOX-4	2.84	2.48	2.97	2.61	2.11	1.91	-0.66	0	79.93	WT	NA
FOLFOX-4	3.14	2.81	3.42	2.98	2.07	1.87	1.20	0	71.33	WT	MUT
FOLFOX-4	2.98	2.77	3.31	2.38	2.18	2.29	0.77	0	84.24	WT	NA
FOLFOX-4	3.33	2.94	3.23	2.65	2.32	2.21	1.88	0	79.01	WT	MUT
FOLFOX-4	3.11	3.03	3.30	2.66	1.70	2.46	0.95	0	81.35	WT	MUT
FOLFOX-4	3.01	3.20	3.25	3.08	2.23	2.04	2.00	1	62.88	WT	MUT
FOLFOX-4	2.91	2.61	3.12	2.28	1.99	2.27	-0.35	1	55.59	WT	MUT
FOLFOX-4	2.83	3.22	3.16	2.80	1.88	2.67	1.39	0	78.46	WT	MUT
FOLFOX-4	3.15	2.73	3.29	2.46	2.26	2.52	1.44	1	61.7	MUT	WT
FOLFOX-4	2.96	2.31	3.13	2.35	2.34	1.97	-0.34	0	0.03	MUT	NA
FOLFOX-4	2.30	2.34	2.44	1.93	1.54	1.41	-4.87	0	82.5	WT	WT
FOLFOX-4	3.01	2.47	3.07	2.70	1.91	1.72	-0.82	0	76.58	WT	MUT
FOLFOX-4	2.98	2.48	3.21	2.83	1.79	1.93	-0.46	0	81.74	WT	WT
FOLFOX-4	2.88	2.70	3.11	2.89	1.88	1.72	-0.42	0	59.37	WT	MUT
FOLFOX-4	2.33	2.38	3.14	2.25	1.90	1.77	-2.25	0	65.05	WT	WT
FOLFOX-4	2.53	2.11	2.79	1.98	1.69	1.82	-3.57	0	80.76	WT	NA
FOLFOX-4	3.05	2.63	3.39	2.34	2.05	2.39	0.60	0	80.79	WT	MUT
FOLFOX-4	2.92	2.71	3.15	2.56	1.86	1.91	-0.47	0	73.36	WT	MUT
FOLFOX-4	3.46	2.83	3.47	2.71	2.30	2.37	2.47	0	68.8	WT	MUT
FOLFOX-4	3.05	2.86	3.49	2.26	2.11	2.76	1.58	0	78	WT	WT
FOLFOX-4	3.15	2.73	3.20	2.27	2.32	2.35	1.01	0	84.11	WT	WT















FOLFOX-4+Bevacizumab	2.69	2.57	2.95	2.31	1.86	1.62	-1.94	0	72.61	WT	MUT	
FOLFOX-4+Bevacizumab	3.08	2.65	3.47	2.48	2.22	2.21	1.06	0	66.37	WT	NA	
FOLFOX-4+Bevacizumab	2.97	2.73	2.94	2.80	2.02	2.35	0.43	0	62.59	WT	NA	
FOLFOX-4+Bevacizumab	3.23	2.88	3.25	2.36	2.21	1.94	0.81	0	60.25	WT	MUT	
FOLFOX-4+Bevacizumab	3.25	3.08	3.42	2.86	2.16	2.03	2.00	0	68.17	WT	NA	
FOLFOX-4+Bevacizumab	2.82	2.69	3.28	2.50	2.03	1.97	-0.13	0	72.02	WT	MUT	
FOLFOX-4+Bevacizumab	3.33	2.77	3.30	2.45	1.86	2.26	0.69	0	74.55	WT	MUT	
FOLFOX-4+Bevacizumab	2.77	3.09	3.09	3.00	1.89	1.80	0.23	0	76.75	WT	NA	
FOLFOX-4+Bevacizumab	3.17	2.97	3.22	2.71	2.08	1.74	0.75	0	83.25	WT	NA	
FOLFOX-4+Bevacizumab	2.89	2.79	3.39	2.57	1.74	1.65	-0.57	0	78.19	WT	NA	
FOLFOX-4+Bevacizumab	2.53	2.67	2.85	2.26	1.76	1.85	-2.16	0	78.55	NA	NA	
FOLFOX-4+Bevacizumab	2.86	2.38	3.12	2.49	2.02	1.69	-1.17	0	67.38	WT	NA	
FOLFOX-4+Bevacizumab	2.85	2.45	3.17	2.57	1.90	2.24	-0.46	0	69.26	WT	NA	
FOLFOX-4+Bevacizumab	2.86	2.71	3.36	2.51	1.69	2.05	-0.46	0	81.12	WT	WT	
FOLFOX-4+Bevacizumab	3.53	2.88	2.62	2.91	2.21	1.71	0.63	0	68.76	WT	MUT	
FOLFOX-4+Bevacizumab	2.82	2.85	3.06	2.63	1.89	1.96	-0.36	0	80	WT	NA	
FOLFOX-4+Bevacizumab	3.22	2.77	3.42	2.64	2.15	1.85	0.97	0	79.87	WT	MUT	
FOLFOX-4+Bevacizumab	2.64	2.31	2.81	2.38	1.78	1.83	-2.43	0	78.16	WT	MUT	
FOLFOX-4+Bevacizumab	2.86	2.95	2.98	2.68	2.03	1.72	-0.21	0	65.97	WT	NA	
FOLFOX-4+Bevacizumab	3.06	2.77	3.08	2.29	2.22	2.29	0.52	0	79.74	MUT	NA	
FOLFOX-4+Bevacizumab	3.29	2.93	3.15	2.60	2.11	2.67	1.78	1	23.72	WT	WT	
FOLFOX-4+Bevacizumab	2.85	2.58	3.10	2.70	2.03	1.85	-0.44	0	77.24	WT	WT	
FOLFOX-4+Bevacizumab	3.31	3.28	3.29	2.82	2.08	1.77	1.66	0	65.61	WT	MUT	
FOLFOX-4+Bevacizumab	3.16	2.88	3.50	2.92	1.89	1.80	0.95	0	72.05	WT	WT	
FOLFOX-4+Bevacizumab	3.26	2.67	3.17	2.47	2.19	2.44	1.12	0	65.45	WT	NA	
FOLFOX-4+Bevacizumab	2.99	2.83	2.86	2.25	1.92	2.05	-0.73	0	81.25	MUT	WT	
FOLFOX-4+Bevacizumab	3.06	2.69	2.97	2.62	1.80	2.35	-0.10	0	79.84	WT	MUT	
FOLFOX-4+Bevacizumab	3.11	2.61	3.16	2.21	1.73	2.28	-0.57	0	84.47	NA	NA	
FOLFOX-4+Bevacizumab	2.99	2.70	3.16	2.53	2.14	2.56	0.86	0	59.99	WT	WT	
FOLFOX-4+Bevacizumab	2.99	2.56	2.97	1.83	1.95	2.08	-1.37	0	66.69	WT	NA	
FOLFOX-4+Bevacizumab	3.35	2.53	2.99	2.42	2.06	2.04	-0.05	0	66.1	WT	MUT	
FOLFOX-4+Bevacizumab	3.03	2.96	3.03	2.40	2.20	2.40	0.91	0	62.26	WT	MUT	
FOLFOX-4+Bevacizumab	2.75	2.64	3.21	2.50	1.83	1.78	-1.02	0	80.33	WT	WT	
FOLFOX-4+Bevacizumab	3.07	2.73	3.19	1.74	2.01	2.10	-0.63	0	83.98	WT	WT	
FOLFOX-4+Bevacizumab	2.60	2.52	3.08	2.16	1.51	1.83	-2.57	0	60.42	WT	NA	
FOLFOX-4+Bevacizumab	3.16	2.82	3.57	2.54	2.25	2.69	2.31	0	54.08	WT	WT	
FOLFOX-4+Bevacizumab	3.06	2.57	3.04	2.39	2.42	2.28	0.64	1	22.11	NA	WT	
FOLFOX-4+Bevacizumab	2.96	2.82	2.92	2.52	2.00	2.60	0.43	0	78.69	WT	NA	
FOLFOX-4+Bevacizumab	2.78	2.38	2.70	2.45	2.06	1.84	-1.67	0	82.4	WT	NA	
FOLFOX-4+Bevacizumab	3.20	3.01	3.19	1.95	1.94	2.47	0.51	0	59.7	WT	MUT	
FOLFOX-4+Bevacizumab	2.75	2.57	3.10	2.43	1.77	1.94	-1.28	0	74.78	WT	NA	
FOLFOX-4+Bevacizumab	3.68	3.01	3.40	2.51	2.24	2.46	2.69	1	34.23	NA	WT	
FOLFOX-4+Bevacizumab	2.83	2.51	2.90	2.26	2.14	1.85	-1.17	0	64.16	WT	NA	
FOLFOX-4+Bevacizumab	3.13	2.84	3.57	3.05	2.06	1.96	1.63	1	67.38	WT	MUT	
FOLFOX-4+Bevacizumab	3.63	3.20	2.97	3.08	2.23	2.55	3.03	0	81.18	WT	MUT	
FOLFOX-4+Bevacizumab	2.97	2.61	3.41	2.37	2.08	1.93	0.04	0	61.57	WT	NA	

FOLFOX-4+Bevacizumab	2.71	2.63	2.59	2.57	1.84	1.59	-2.15	0	76.88	WT	NA	
FOLFOX-4+Bevacizumab	2.82	2.51	2.54	2.51	1.98	2.26	-1.25	0	80.3	WT	MUT	
FOLFOX-4+Bevacizumab	3.08	2.89	3.33	2.24	2.34	2.00	0.91	0	60.94	MUT	WT	
FOLFOX-4+Bevacizumab	2.52	2.49	2.85	1.74	1.76	2.14	-2.68	0	70.21	WT	WT	
FOLFOX-4+Bevacizumab	2.68	2.64	3.08	2.36	1.75	1.83	-1.58	0	85.26	WT	NA	
FOLFOX-4+Bevacizumab	3.00	2.61	2.79	2.34	1.92	2.36	-0.67	0	77.11	WT	MUT	
FOLFOX-4+Bevacizumab	3.17	2.69	2.95	2.35	1.90	2.58	0.17	0	65.81	WT	MUT	
FOLFOX-4+Bevacizumab	3.19	2.15	3.53	2.57	2.27	2.54	1.13	0	79.21	MUT	NA	
FOLFOX-4+Bevacizumab	2.34	2.46	2.82	2.12	1.60	1.87	-3.21	0	60.71	WT	NA	
FOLFOX-4+Bevacizumab	2.70	2.41	2.86	2.35	1.74	2.06	-1.97	0	78	WT	MUT	
FOLFOX-4+Bevacizumab	3.16	2.49	2.90	2.08	1.93	1.92	-1.30	0	79.77	WT	MUT	
FOLFOX-4+Bevacizumab	3.28	3.04	3.44	2.98	2.15	1.80	1.85	0	76.19	WT	MUT	
FOLFOX-4+Bevacizumab	2.70	2.68	2.91	2.61	1.92	1.54	-1.44	0	80.03	WT	MUT	
FOLFOX-4+Bevacizumab	3.07	3.08	3.20	3.21	2.15	1.82	1.55	0	79.38	WT	WT	
FOLFOX-4+Bevacizumab	3.26	2.73	3.10	2.48	2.13	2.39	0.94	0	76.39	WT	MUT	
FOLFOX-4+Bevacizumab	2.73	2.46	2.89	2.12	1.77	2.26	-1.78	0	74.38	WT	MUT	
FOLFOX-4+Bevacizumab	2.91	2.76	3.28	2.78	2.05	1.56	-0.04	0	83.61	WT	WT	
FOLFOX-4+Bevacizumab	3.01	2.92	3.29	2.78	2.11	2.08	1.10	0	46.16	WT	MUT	
FOLFOX-4+Bevacizumab	3.03	3.10	3.33	2.53	2.17	2.85	2.20	1	65.18	MUT	WT	
FOLFOX-4+Bevacizumab	2.99	2.34	3.26	2.24	2.13	2.46	0.01	0	84.5	WT	MUT	
FOLFOX-4+Bevacizumab	3.15	2.25	3.30	2.57	2.04	1.97	-0.23	0	78.39	WT	MUT	
FOLFOX-4+Bevacizumab	2.76	2.49	3.33	2.47	1.65	2.14	-0.99	0	79.18	WT	MUT	
FOLFOX-4+Bevacizumab	3.41	2.86	3.45	3.13	2.35	1.85	2.39	0	82.4	WT	MUT	
FOLFOX-4+Bevacizumab	2.83	2.72	2.82	2.34	1.83	2.16	-1.08	0	77.6	WT	MUT	
FOLFOX-4+Bevacizumab	3.32	2.49	2.91	2.22	2.16	2.06	-0.29	0	82.07	WT	MUT	
FOLFOX-4+Bevacizumab	3.04	2.62	3.32	2.82	2.14	2.11	0.87	0	62.59	WT	NA	
FOLFOX-4+Bevacizumab	2.77	2.66	3.27	2.61	1.95	1.97	-0.29	0	82.17	WT	NA	
FOLFOX-4+Bevacizumab	3.20	2.87	3.34	2.16	2.18	2.44	1.19	0	77.11	WT	MUT	
FOLFOX-4+Bevacizumab	3.06	2.65	2.99	1.90	2.01	2.17	-0.79	0	66.1	WT	WT	
FOLFOX-4+Bevacizumab	3.06	3.03	3.11	2.87	2.05	1.93	0.88	0	67.42	MUT	NA	
FOLFOX-4+Bevacizumab	3.19	2.79	3.20	2.65	2.05	1.98	0.62	0	77.86	WT	NA	
FOLFOX-4+Bevacizumab	2.88	2.81	3.28	2.33	1.89	2.53	0.34	0	60.55	WT	MUT	
FOLFOX-4+Bevacizumab	3.12	2.86	3.31	2.73	1.94	2.03	0.77	0	71.89	WT	MUT	
FOLFOX-4+Bevacizumab	3.06	2.88	3.15	2.21	2.01	1.78	-0.32	0	77.47	WT	NA	
FOLFOX-4+Bevacizumab	2.85	2.86	3.27	2.43	1.78	2.21	-0.13	0	77.9	WT	MUT	
FOLFOX-4+Bevacizumab	2.71	2.24	3.01	1.89	2.19	1.82	-1.95	0	84.44	WT	NA	
FOLFOX-4+Bevacizumab	3.34	2.51	3.09	2.28	1.98	2.55	0.37	0	80.33	WT	MUT	
FOLFOX-4+Bevacizumab	3.17	2.62	3.07	2.16	2.08	2.41	0.14	0	71.43	WT	MUT	
FOLFOX-4+Bevacizumab	3.19	2.93	3.06	2.28	2.28	2.39	1.15	0	85.52	WT	WT	
FOLFOX-4+Bevacizumab	3.47	2.92	3.42	2.62	2.14	2.35	2.10	0	61.96	WT	MUT	
FOLFOX-4+Bevacizumab	3.11	2.93	3.35	2.63	2.17	2.04	1.24	0	72.54	WT	MUT	
FOLFOX-4+Bevacizumab	3.22	2.46	3.60	2.05	2.39	2.22	0.99	0	83.38	MUT	WT	
FOLFOX-4+Bevacizumab	2.73	2.68	3.10	2.53	1.86	1.93	-0.87	0	68.34	WT	NA	
FOLFOX-4+Bevacizumab	3.13	2.79	2.86	2.67	2.36	2.23	0.96	1	50.3	MUT	WT	
FOLFOX-4+Bevacizumab	3.10	2.90	3.93	2.77	2.69	2.06	3.21	0	74.81	WT	NA	
FOLFOX-4+Bevacizumab	3.23	2.79	3.33	2.39	2.16	2.65	1.57	1	45.86	WT	MUT	

FOLFOX-4+Bevacizumab	3.19	2.51	3.58	2.75	1.69	1.67	-0.18	0	82.37	WT	NA	
FOLFOX-4+Bevacizumab	2.94	2.76	3.02	2.64	2.11	1.86	-0.07	0	78.49	MUT	NA	
FOLFOX-4+Bevacizumab	2.98	2.84	3.37	2.53	2.03	1.93	0.42	0	60.71	WT	WT	
FOLFOX-4+Bevacizumab	2.86	2.64	3.19	2.65	1.95	2.29	0.12	0	84.21	WT	NA	
FOLFOX-4+Bevacizumab	3.17	3.12	3.35	2.78	2.05	2.55	2.16	0	72.94	WT	MUT	
FOLFOX-4+Bevacizumab	3.38	3.12	2.97	2.66	2.14	2.12	1.39	0	69.49	WT	WT	
FOLFOX-4+Bevacizumab	2.94	2.57	3.12	1.89	1.93	2.77	-0.33	0	70.37	WT	MUT	
FOLFOX-4+Bevacizumab	3.32	2.58	3.60	2.44	2.21	2.38	1.61	0	64.89	WT	WT	
FOLFOX-4+Bevacizumab	3.19	2.58	3.38	2.24	1.98	2.07	0.05	0	82.43	WT	MUT	
FOLFOX-4+Bevacizumab	3.00	2.78	3.15	2.40	2.22	2.31	0.71	0	85.82	WT	WT	
FOLFOX-4+Bevacizumab	3.03	2.58	3.32	2.71	2.03	2.10	0.43	0	77.8	WT	MUT	
FOLFOX-4+Bevacizumab	3.33	2.94	3.20	2.56	1.96	1.87	0.64	1	27.43	WT	MUT	
FOLFOX-4+Bevacizumab	3.12	2.58	2.87	2.52	2.10	2.03	-0.29	0	60.98	WT	NA	
FOLFOX-4+Bevacizumab	3.07	2.43	2.98	2.19	2.12	2.25	-0.48	0	68.53	WT	WT	
FOLFOX-4+Bevacizumab	3.21	2.64	2.97	2.18	2.26	2.32	0.33	0	63.74	WT	NA	
FOLFOX-4+Bevacizumab	3.05	2.53	3.35	2.26	2.17	2.09	0.17	0	71.56	WT	MUT	
FOLFOX-4+Bevacizumab	3.02	2.81	3.16	2.48	1.93	2.76	0.88	1	76.19	WT	MUT	
FOLFOX-4+Bevacizumab	2.95	2.60	3.23	2.46	1.96	2.06	-0.25	0	82.73	WT	NA	
FOLFOX-4+Bevacizumab	3.14	2.85	3.36	2.78	2.04	2.18	1.27	0	60.16	WT	MUT	
FOLFOX-4+Bevacizumab	3.03	2.98	3.20	2.59	1.68	2.08	0.04	1	80.76	WT	NA	
FOLFOX-4+Bevacizumab	3.38	2.29	3.17	2.23	1.99	2.36	-0.07	1	30.09	WT	MUT	
FOLFOX-4+Bevacizumab	2.97	2.89	3.03	1.77	2.35	1.76	-0.50	0	67.32	NA	WT	
FOLFOX-4+Bevacizumab	3.15	2.56	3.32	2.52	1.90	1.82	-0.23	0	75.07	WT	WT	
FOLFOX-4+Bevacizumab	3.48	2.82	3.13	2.77	2.12	2.65	2.04	0	59.66	WT	MUT	
FOLFOX-4+Bevacizumab	3.68	2.89	3.28	2.83	2.26	2.42	2.68	0	63.11	WT	MUT	
FOLFOX-4+Bevacizumab	2.97	2.51	2.91	2.34	2.06	2.28	-0.50	1	12.45	WT	WT	
FOLFOX-4+Bevacizumab	3.44	2.77	3.36	2.63	2.20	2.48	2.04	1	75.47	MUT	WT	
FOLFOX-4+Bevacizumab	3.13	2.61	3.16	2.10	2.09	2.29	0.01	0	84.67	WT	NA	
FOLFOX-4+Bevacizumab	3.21	3.01	3.45	2.51	2.29	2.46	2.23	0	60.19	MUT	NA	
FOLFOX-4+Bevacizumab	3.03	3.05	2.96	2.63	1.91	2.45	0.73	0	60.91	WT	NA	
FOLFOX-4+Bevacizumab	3.57	2.83	3.32	2.87	2.28	2.12	2.24	0	29.34	WT	NA	
FOLFOX-4+Bevacizumab	3.42	2.96	3.29	2.59	2.18	2.44	2.07	0	66.04	WT	MUT	
FOLFOX-4+Bevacizumab	3.04	2.52	3.30	2.60	2.15	2.00	0.32	0	60.25	WT	WT	
FOLFOX-4+Bevacizumab	2.96	2.72	3.10	2.57	2.01	2.13	0.07	0	63.57	WT	WT	
FOLFOX-4+Bevacizumab	3.26	2.76	3.29	2.45	2.05	2.03	0.63	0	2.79	WT	MUT	
FOLFOX-4+Bevacizumab	3.24	2.91	3.19	2.85	2.07	1.64	0.72	1	83.12	WT	MUT	
FOLFOX-4+Bevacizumab	3.22	2.58	2.82	2.11	2.30	2.18	-0.11	1	1.15	WT	NA	
FOLFOX-4+Bevacizumab	3.27	2.82	3.41	2.78	1.84	1.85	0.67	0	77.54	WT	MUT	
FOLFOX-4+Bevacizumab	3.50	2.82	3.27	2.75	2.63	1.99	2.42	1	42.81	MUT	NA	
FOLFOX-4+Bevacizumab	2.87	2.11	2.94	2.34	1.90	1.96	-1.88	0	60.52	WT	NA	
FOLFOX-4+Bevacizumab	2.46	2.13	2.65	1.88	2.03	1.66	-3.50	0	59.79	MUT	NA	
FOLFOX-4+Bevacizumab	3.12	2.71	3.27	2.63	1.91	1.98	0.24	0	63.44	WT	WT	
FOLFOX-4+Bevacizumab	3.23	2.95	3.25	2.98	2.45	1.80	1.91	0	59.7	WT	MUT	
FOLFOX-4+Bevacizumab	2.99	2.62	3.32	2.80	1.92	2.04	0.28	0	72.54	WT	WT	
FOLFOX-4+Bevacizumab	3.20	2.89	3.37	2.76	1.92	2.11	1.10	0	77.54	WT	NA	
FOLFOX-4+Bevacizumab	3.25	3.13	3.42	2.91	2.21	2.37	2.62	0	60.94	WT	MUT	



FOLFOX-4+Bevacizumab	3.05	2.75	3.26	1.96	2.02	1.86	-0.54	0	78.88	WT	WT
FOLFOX-4+Bevacizumab	3.36	2.90	3.35	2.39	1.91	2.33	1.08	0	79.93	WT	MUT
FOLFOX-4+Bevacizumab	3.48	2.58	3.51	2.14	2.26	1.88	0.83	0	72.9	WT	MUT
FOLFOX-4+Bevacizumab	3.23	3.10	3.31	2.87	2.36	1.95	2.12	0	59.63	NA	WT
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	79.77	MUT	WT
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	80.89	WT	NA
XELOX+Bevacizumab	3.21	2.90	3.17	2.67	1.76	1.92	0.16	1	43.43	WT	NA
XELOX+Bevacizumab	3.36	2.93	3.65	2.41	2.49	2.51	2.93	1	32.26	WT	MUT
XELOX+Bevacizumab	2.74	2.63	3.24	2.75	2.16	2.29	0.53	0	62.39	WT	WT
XELOX+Bevacizumab	3.04	2.80	2.92	2.82	2.17	2.30	0.85	0	66.2	WT	MUT
XELOX+Bevacizumab	2.92	2.49	3.08	2.31	1.96	2.09	-0.80	1	63.41	WT	MUT
XELOX+Bevacizumab	2.92	2.67	3.05	2.04	1.99	2.46	-0.40	0	85.62	WT	NA
XELOX+Bevacizumab	3.04	2.59	3.22	2.80	1.62	1.86	-0.63	1	24.57	WT	NA
XELOX+Bevacizumab	2.82	2.44	2.91	1.84	1.76	1.79	-2.58	0	74.81	WT	NA
XELOX+Bevacizumab	3.12	2.83	3.35	3.00	2.29	2.20	1.95	0	77.54	WT	MUT
XELOX+Bevacizumab	2.94	2.73	3.45	2.69	1.83	1.88	0.06	0	77.67	WT	WT
XELOX+Bevacizumab	3.13	2.87	3.26	2.56	2.00	2.67	1.37	0	66.86	WT	MUT
XELOX+Bevacizumab	2.81	2.60	3.32	2.67	2.01	2.03	0.00	0	67.09	WT	WT
XELOX+Bevacizumab	2.89	2.40	2.86	2.63	2.03	1.84	-1.11	0	62.88	MUT	NA
XELOX+Bevacizumab	3.22	2.84	3.22	2.81	2.10	1.64	0.63	1	74.35	WT	WT
XELOX+Bevacizumab	3.38	2.66	3.14	2.36	2.18	2.29	0.87	0	73.26	WT	WT
XELOX+Bevacizumab	3.37	3.26	2.96	2.72	2.21	2.16	1.83	1	79.18	WT	NA
XELOX+Bevacizumab	3.06	2.72	3.30	2.58	2.15	1.81	0.39	0	86.51	WT	MUT
XELOX+Bevacizumab	2.98	2.45	3.24	2.11	2.09	1.95	-0.70	0	80.76	WT	NA
XELOX+Bevacizumab	2.99	2.61	3.27	2.48	1.95	2.27	0.15	0	72.84	WT	NA
XELOX+Bevacizumab	3.24	2.87	3.11	2.83	2.21	1.86	1.05	0	64.69	WT	MUT
XELOX+Bevacizumab	3.01	2.57	3.27	2.03	2.01	2.19	-0.41	0	59.79	WT	WT
XELOX+Bevacizumab	3.05	3.03	3.03	2.68	2.05	2.76	1.52	0	64.69	WT	MUT
XELOX+Bevacizumab	3.32	2.80	3.08	2.53	1.83	2.46	0.66	0	82.99	WT	NA
XELOX+Bevacizumab	3.26	2.68	3.25	2.45	2.03	2.03	0.41	0	79.24	WT	NA
XELOX+Bevacizumab	3.21	2.99	3.00	2.74	1.95	2.52	1.22	0	77.77	WT	MUT
XELOX+Bevacizumab	3.41	2.68	3.52	2.60	2.37	2.28	2.15	0	60.06	MUT	WT
XELOX+Bevacizumab	2.86	2.58	3.03	2.23	2.12	1.98	-0.76	0	79.34	WT	WT
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	80.59	WT	MUT
XELOX+Bevacizumab	3.06	2.68	3.54	2.63	2.06	2.78	1.73	0	60.22	WT	MUT
XELOX+Bevacizumab	3.34	2.75	3.33	2.57	2.08	2.34	1.37	0	79.21	WT	MUT
XELOX+Bevacizumab	2.93	2.70	3.26	2.30	2.14	2.19	0.23	0	78	WT	WT
XELOX+Bevacizumab	3.07	2.63	3.13	2.41	2.01	2.37	0.23	0	63.21	WT	NA
XELOX+Bevacizumab	3.07	2.90	3.28	2.62	2.37	2.15	1.53	0	78.75	WT	MUT
XELOX+Bevacizumab	2.99	2.75	3.35	2.93	1.90	1.79	0.34	0	71.98	WT	NA
XELOX+Bevacizumab	2.79	2.76	3.28	2.57	2.04	2.23	0.35	0	79.31	WT	MUT
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	77.5	WT	NA
XELOX+Bevacizumab	3.00	2.66	3.10	2.30	1.75	2.67	-0.14	1	18.76	WT	MUT
XELOX+Bevacizumab	3.50	2.49	3.47	2.86	2.74	2.24	2.87	0	60.98	WT	WT
XELOX+Bevacizumab	3.16	2.70	3.00	2.71	2.29	2.09	0.80	0	67.75	NA	WT
XELOX+Bevacizumab	3.17	2.84	3.32	2.45	1.76	2.26	0.41	0	65.68	WT	WT

XELOX+Bevacizumab	2.82	2.53	3.03	2.25	1.86	2.54	-0.68	0	78.85	WT	MUT	
XELOX+Bevacizumab	2.93	2.77	3.19	2.80	1.98	1.93	0.20	0	81.87	WT	WT	
XELOX+Bevacizumab	2.98	2.82	3.11	2.40	1.97	2.14	-0.01	1	44.45	WT	WT	
XELOX+Bevacizumab	3.26	3.00	3.57	2.70	2.58	3.26	4.21	0	75.24	MUT	WT	
XELOX+Bevacizumab	2.87	2.59	3.27	2.67	1.70	2.09	-0.52	0	73.49	WT	NA	
XELOX+Bevacizumab	3.55	3.25	3.22	2.92	2.40	2.69	3.69	0	60.22	MUT	NA	
XELOX+Bevacizumab	2.73	2.62	2.81	2.56	1.65	1.94	-1.75	0	78.06	WT	NA	
XELOX+Bevacizumab	2.89	2.75	3.15	2.43	1.79	2.16	-0.46	0	67.94	WT	MUT	
XELOX+Bevacizumab	3.40	3.27	3.10	2.98	1.99	1.79	1.53	1	52.99	WT	MUT	
XELOX+Bevacizumab	3.05	2.82	3.30	2.88	1.89	1.70	0.26	0	80.99	WT	NA	
XELOX+Bevacizumab	3.69	2.94	3.13	2.81	2.15	2.69	2.67	0	81.45	WT	MUT	
XELOX+Bevacizumab	3.09	3.06	3.40	2.90	1.97	2.01	1.37	0	48.59	WT	MUT	
XELOX+Bevacizumab	3.06	3.04	3.28	3.02	2.02	2.03	1.37	0	60.02	WT	NA	
XELOX+Bevacizumab	2.46	2.32	3.10	2.26	1.59	1.63	-2.97	0	81.48	WT	WT	
XELOX+Bevacizumab	3.01	2.63	3.30	2.35	2.39	1.74	0.28	0	64	MUT	NA	
XELOX+Bevacizumab	2.75	2.51	2.96	2.63	1.86	1.56	-1.66	0	81.48	WT	NA	
XELOX+Bevacizumab	3.22	2.95	3.04	3.00	2.14	2.56	1.96	0	72.44	WT	MUT	
XELOX+Bevacizumab	2.93	2.72	3.52	2.80	1.97	1.95	0.63	0	61.73	WT	NA	
XELOX+Bevacizumab	3.59	2.86	3.31	2.65	2.04	1.88	1.28	0	83.38	WT	MUT	
XELOX+Bevacizumab	2.88	3.05	2.92	2.63	2.11	2.65	1.07	1	72.67	WT	NA	
XELOX+Bevacizumab	2.96	2.77	3.07	2.59	2.09	1.90	0.01	0	60.29	WT	WT	
XELOX+Bevacizumab	3.32	2.78	3.31	2.56	2.23	2.46	1.75	0	61.17	MUT	NA	
XELOX+Bevacizumab	3.32	2.95	2.91	2.58	2.24	2.39	1.38	0	75.01	NA	NA	
XELOX+Bevacizumab	2.81	2.42	3.41	2.54	2.30	2.19	0.46	0	77.21	WT	WT	
XELOX+Bevacizumab	3.22	2.84	3.40	3.05	2.08	1.78	1.31	0	82.63	WT	WT	
XELOX+Bevacizumab	2.82	3.00	2.94	2.76	1.91	2.54	0.59	0	85.59	WT	MUT	
XELOX+Bevacizumab	3.14	2.79	3.27	2.86	2.00	1.80	0.61	0	59.37	WT	WT	
XELOX+Bevacizumab	2.88	2.92	3.19	2.62	2.08	2.21	0.67	0	68.5	WT	MUT	
XELOX+Bevacizumab	3.10	2.61	3.17	2.69	1.82	1.69	-0.56	0	83.19	WT	NA	
XELOX+Bevacizumab	3.13	2.86	3.31	2.94	1.89	2.33	1.27	0	84.93	WT	MUT	
XELOX+Bevacizumab	2.73	2.67	2.95	2.70	2.03	1.85	-0.70	0	76.48	WT	NA	
XELOX+Bevacizumab	3.32	2.71	3.34	2.68	2.50	2.92	2.91	0	60.09	MUT	WT	
XELOX+Bevacizumab	3.37	2.80	3.33	2.62	2.17	2.65	2.07	0	82.83	WT	MUT	
XELOX+Bevacizumab	3.11	2.79	3.27	2.59	2.14	2.06	0.82	0	73.2	WT	WT	
XELOX+Bevacizumab	2.72	2.58	3.23	1.63	1.73	2.95	-0.91	0	75.07	WT	NA	
XELOX+Bevacizumab	2.97	2.64	2.99	2.68	2.26	2.21	0.52	0	76.42	MUT	NA	
XELOX+Bevacizumab	3.10	2.72	3.14	2.57	2.03	2.29	0.55	0	76.42	WT	NA	
XELOX+Bevacizumab	3.07	2.82	3.25	2.73	1.72	1.79	-0.17	0	65.74	WT	NA	
XELOX+Bevacizumab	2.95	2.67	2.77	1.91	1.94	2.56	-0.90	0	71.89	WT	NA	
XELOX+Bevacizumab	2.93	2.63	2.97	2.31	1.57	2.34	-1.19	0	77.27	WT	MUT	
XELOX+Bevacizumab	2.72	2.73	3.10	2.32	1.81	1.93	-1.16	1	50.04	WT	NA	
XELOX+Bevacizumab	3.05	2.71	3.40	2.53	2.26	2.64	1.66	0	61.93	MUT	NA	
XELOX+Bevacizumab	3.03	2.72	3.21	2.48	2.06	2.43	0.69	0	75.1	WT	MUT	
XELOX+Bevacizumab	3.21	2.70	2.94	2.58	2.13	1.95	0.16	0	79.41	WT	MUT	
XELOX+Bevacizumab	3.55	3.00	3.29	2.47	2.47	1.52	1.58	0	78.26	MUT	WT	
XELOX+Bevacizumab	3.18	2.63	3.01	2.24	2.12	2.31	0.14	0	80.33	WT	NA	

XELOX+Bevacizumab	3.11	2.90	3.06	2.89	2.24	1.83	0.92	0	66.14	WT	NA	
XELOX+Bevacizumab	3.02	2.81	3.45	2.62	1.82	1.90	0.23	0	77.96	WT	MUT	
XELOX+Bevacizumab	2.79	2.45	3.18	2.41	1.94	2.11	-0.79	0	79.74	WT	MUT	
XELOX+Bevacizumab	2.75	2.56	3.08	2.49	2.00	1.92	-0.86	0	69.91	WT	NA	
XELOX+Bevacizumab	2.66	3.11	3.47	2.71	1.63	1.56	-0.45	0	83.81	WT	NA	
XELOX+Bevacizumab	2.71	2.54	3.30	2.44	1.91	1.63	-1.17	0	77.93	WT	NA	
XELOX+Bevacizumab	3.24	2.87	3.28	2.82	1.95	1.95	0.90	0	69.03	WT	MUT	
XELOX+Bevacizumab	3.10	2.88	3.50	2.53	2.23	2.47	1.89	0	78.16	WT	NA	
XELOX+Bevacizumab	3.35	2.47	2.99	2.78	2.19	2.11	0.61	1	29.11	WT	MUT	
XELOX+Bevacizumab	2.67	2.42	3.07	2.09	1.91	2.42	-1.22	0	61.9	WT	NA	
XELOX+Bevacizumab	3.08	2.93	3.06	2.50	1.81	2.14	0.05	0	78.85	WT	MUT	
XELOX+Bevacizumab	3.05	2.70	2.86	2.42	2.01	1.83	-0.72	0	65.12	WT	MUT	
XELOX+Bevacizumab	3.05	3.14	3.28	2.75	2.12	2.46	1.91	0	61.21	MUT	NA	
XELOX+Bevacizumab	3.35	3.07	3.10	2.80	2.10	2.19	1.63	0	66.17	WT	WT	
XELOX+Bevacizumab	3.28	3.21	3.51	3.11	2.00	2.30	2.68	0	72.02	WT	NA	
XELOX+Bevacizumab	3.09	2.55	3.29	2.26	2.21	1.96	0.07	0	53.72	WT	MUT	
XELOX+Bevacizumab	3.06	2.60	3.44	2.97	2.01	1.80	0.60	0	76.22	WT	WT	
XELOX+Bevacizumab	2.91	3.06	3.08	2.81	1.76	2.73	1.03	0	83.94	WT	WT	
XELOX+Bevacizumab	2.90	2.66	3.37	2.29	1.68	2.68	0.01	0	69.75	WT	WT	
XELOX+Bevacizumab	2.88	2.98	3.09	2.85	1.82	1.83	-0.04	0	77.31	WT	WT	
XELOX+Bevacizumab	3.49	2.82	3.35	2.93	2.04	2.01	1.64	0	72.67	WT	MUT	
XELOX+Bevacizumab	2.99	2.65	3.16	2.69	2.04	2.02	0.15	0	64.53	WT	WT	
XELOX+Bevacizumab	3.06	2.54	2.97	2.11	1.76	1.82	-1.66	0	61.14	WT	NA	
XELOX+Bevacizumab	2.80	2.64	2.86	2.65	1.76	1.65	-1.59	0	80.89	WT	NA	
XELOX+Bevacizumab	3.18	2.49	3.35	1.88	2.12	2.37	0.08	0	75.4	WT	NA	
XELOX+Bevacizumab	3.16	2.74	3.01	2.32	2.20	2.03	0.20	0	59.93	WT	MUT	
XELOX+Bevacizumab	2.57	2.67	2.87	2.22	2.27	2.37	-0.50	0	77.9	WT	NA	
XELOX+Bevacizumab	3.09	2.94	3.08	3.17	1.81	1.75	0.39	0	61.17	WT	MUT	
XELOX+Bevacizumab	2.40	2.44	2.68	1.80	1.54	2.38	-3.23	0	60.25	WT	WT	
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	73	WT	MUT	
XELOX+Bevacizumab	2.82	2.31	2.96	2.27	1.96	1.93	-1.64	0	83.55	WT	NA	
XELOX+Bevacizumab	3.04	2.76	3.08	2.13	1.81	2.43	-0.31	0	79.64	WT	MUT	
XELOX+Bevacizumab	3.19	3.29	3.50	2.91	2.26	2.50	3.18	0	76.65	WT	MUT	
XELOX+Bevacizumab	3.19	2.67	4.06	2.86	1.91	1.92	1.65	0	84.44	WT	WT	
XELOX+Bevacizumab	2.34	2.34	2.75	2.01	1.93	1.81	-3.07	0	68.14	WT	NA	
XELOX+Bevacizumab	3.14	3.01	3.39	3.12	1.90	1.75	1.17	0	73.63	WT	MUT	
XELOX+Bevacizumab	3.10	2.41	3.07	2.62	2.12	2.52	0.48	0	64.66	WT	MUT	
XELOX+Bevacizumab	3.17	2.93	3.43	2.45	1.61	2.04	0.16	0	85.78	WT	MUT	
XELOX+Bevacizumab	3.39	2.75	3.28	2.56	1.97	2.53	1.37	0	60.55	WT	MUT	
XELOX+Bevacizumab	3.17	2.87	3.19	2.96	1.95	1.53	0.34	0	59.99	WT	WT	
XELOX+Bevacizumab	3.00	2.38	3.25	2.41	1.94	2.05	-0.59	0	80.16	WT	WT	
XELOX+Bevacizumab	3.19	3.00	3.40	2.97	1.89	1.91	1.21	0	73.03	WT	MUT	
XELOX+Bevacizumab	2.86	2.89	3.65	2.95	2.16	1.81	1.37	0	77.6	WT	MUT	
XELOX+Bevacizumab	2.78	2.51	2.93	2.27	1.85	1.54	-2.12	0	73.4	WT	MUT	
XELOX+Bevacizumab	3.12	2.73	3.17	2.60	2.00	2.31	0.66	0	78.29	WT	MUT	
XELOX+Bevacizumab	2.84	2.68	3.01	2.48	2.04	2.45	0.05	0	82.56	WT	WT	

XELOX+Bevacizumab	3.16	2.70	3.29	2.39	1.92	2.24	0.34	0	60.25	WT	WT	
XELOX+Bevacizumab	2.36	2.38	2.80	2.23	1.77	1.51	-3.31	0	83.42	WT	NA	
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	77.7	WT	NA	
XELOX+Bevacizumab	2.84	3.01	3.56	2.50	2.18	2.41	1.62	0	79.08	MUT	NA	
XELOX+Bevacizumab	2.88	2.54	2.87	2.08	2.08	2.49	-0.66	0	83.42	MUT	NA	
XELOX+Bevacizumab	2.85	2.68	3.11	2.63	1.81	1.81	-0.81	0	83.19	NA	NA	
XELOX+Bevacizumab	2.93	2.60	3.02	2.49	1.88	1.85	-0.97	0	84.4	WT	WT	
XELOX+Bevacizumab	3.17	3.03	3.20	2.91	1.91	1.98	0.99	1	2.2	WT	MUT	
XELOX+Bevacizumab	3.23	2.80	3.12	2.45	2.15	2.18	0.77	0	60.32	WT	MUT	
XELOX+Bevacizumab	2.59	2.30	2.85	2.48	1.49	1.40	-3.40	0	59.86	WT	NA	
XELOX+Bevacizumab	3.41	2.63	3.19	2.24	2.20	2.61	1.21	0	57.03	WT	NA	
XELOX+Bevacizumab	2.92	2.20	2.66	2.30	1.83	2.05	-2.20	0	61.31	WT	MUT	
XELOX+Bevacizumab	3.08	2.73	3.23	2.66	2.03	2.16	0.62	0	60.48	WT	MUT	
XELOX+Bevacizumab	2.67	2.89	3.10	2.34	1.94	2.80	0.35	0	80.23	WT	MUT	
XELOX+Bevacizumab	2.99	2.32	3.65	2.58	1.97	2.13	0.25	0	76.75	WT	NA	
XELOX+Bevacizumab	3.22	2.95	3.31	2.88	2.24	2.97	2.89	0	61.4	WT	WT	
XELOX+Bevacizumab	3.10	2.88	3.22	2.73	2.25	2.71	2.01	1	36.7	WT	NA	
XELOX+Bevacizumab	2.84	2.42	2.87	1.88	1.85	1.90	-2.31	0	84.17	WT	WT	
XELOX+Bevacizumab	3.09	2.95	3.53	2.95	1.98	1.80	1.22	1	20.6	WT	WT	
XELOX+Bevacizumab	2.94	2.61	3.36	2.72	1.92	1.83	-0.09	0	61.83	WT	NA	
XELOX+Bevacizumab	3.57	2.65	3.36	2.53	2.23	2.56	2.06	1	22.31	MUT	WT	
XELOX+Bevacizumab	2.85	2.54	3.39	3.01	1.98	1.91	0.29	0	84.86	WT	NA	
XELOX+Bevacizumab	3.49	3.00	3.41	3.03	2.12	2.04	2.31	0	82.04	WT	MUT	
XELOX+Bevacizumab	2.62	2.47	2.87	2.38	1.67	1.98	-2.17	0	84.8	WT	NA	
XELOX+Bevacizumab	3.14	2.72	3.13	2.76	2.20	2.00	0.78	0	86.31	MUT	WT	
XELOX+Bevacizumab	2.97	2.91	3.04	2.92	1.71	1.90	-0.17	0	79.9	WT	NA	
XELOX+Bevacizumab	3.29	2.76	3.16	2.49	2.30	2.44	1.49	0	81.97	WT	MUT	
XELOX+Bevacizumab	2.90	2.62	3.20	2.37	1.95	1.90	-0.65	0	76.62	WT	NA	
XELOX+Bevacizumab	2.70	2.58	3.14	2.63	1.71	2.18	-0.89	0	79.08	WT	NA	
XELOX+Bevacizumab	3.01	2.58	3.34	2.14	2.14	2.26	0.18	1	43.01	WT	MUT	
XELOX+Bevacizumab	2.64	2.62	2.77	2.32	1.88	1.95	-1.76	0	59.7	WT	NA	
XELOX+Bevacizumab	3.02	2.65	3.17	2.56	2.29	1.78	0.25	0	61.44	WT	NA	
XELOX+Bevacizumab	2.89	2.70	3.27	2.55	1.83	2.26	-0.02	0	80.03	WT	WT	
XELOX+Bevacizumab	3.02	2.91	3.22	2.74	2.12	2.05	0.94	0	84.24	WT	MUT	
XELOX+Bevacizumab	3.19	2.68	3.41	2.59	2.08	1.96	0.75	0	79.24	WT	NA	
XELOX+Bevacizumab	2.84	2.80	3.31	2.62	2.34	2.37	1.32	0	59.83	MUT	NA	
XELOX+Bevacizumab	2.93	2.70	3.17	2.59	1.79	1.66	-0.86	0	79.9	WT	MUT	
XELOX+Bevacizumab	3.02	3.09	3.07	2.41	2.24	2.38	1.23	0	76.12	WT	MUT	
XELOX+Bevacizumab	2.94	2.56	3.24	2.30	1.71	2.11	-0.90	0	82.99	WT	MUT	
XELOX+Bevacizumab	2.73	2.48	2.77	2.21	1.69	1.66	-2.70	0	80.13	WT	NA	
XELOX+Bevacizumab	2.81	2.63	3.11	2.65	2.14	1.88	-0.22	0	81.61	WT	MUT	
XELOX+Bevacizumab	2.91	3.07	3.35	3.14	2.13	1.83	1.44	0	81.35	WT	MUT	
XELOX+Bevacizumab	3.08	2.72	3.24	2.53	1.98	2.16	0.38	0	84.6	WT	WT	
XELOX+Bevacizumab	2.72	2.79	2.99	2.43	2.02	2.38	-0.15	0	81.41	MUT	NA	
XELOX+Bevacizumab	2.77	2.93	2.99	2.94	2.02	1.30	-0.58	0	69.13	WT	MUT	
XELOX+Bevacizumab	2.95	2.94	3.05	2.89	1.92	1.53	-0.21	0	84.21	WT	MUT	

XELOX+Bevacizumab	2.94	2.34	2.95	2.25	1.76	1.59	-2.28	0	68.01	WT	MUT	
XELOX+Bevacizumab	2.35	2.43	2.93	2.74	1.45	1.43	-3.15	0	83.65	WT	NA	
XELOX+Bevacizumab	2.85	2.77	3.11	2.75	1.86	1.81	-0.47	0	75.53	WT	MUT	
XELOX+Bevacizumab	3.24	2.94	3.19	2.90	2.39	2.70	2.71	0	65.12	MUT	WT	
XELOX+Bevacizumab	2.83	2.54	3.00	2.26	1.90	1.85	-1.44	0	72.25	WT	WT	
XELOX+Bevacizumab	3.44	2.49	3.15	2.70	2.16	2.09	0.84	0	60.71	MUT	WT	
XELOX+Bevacizumab	2.88	2.80	3.25	2.68	1.96	1.99	0.17	0	86.01	WT	NA	
XELOX+Bevacizumab	3.35	2.93	3.35	2.11	2.27	2.27	1.41	0	84.14	WT	WT	
XELOX+Bevacizumab	3.36	2.79	3.50	2.87	1.97	2.90	2.50	0	83.78	WT	MUT	
XELOX+Bevacizumab	3.14	2.95	3.27	2.83	2.03	2.75	2.01	0	68.8	WT	MUT	
XELOX+Bevacizumab	3.03	2.65	3.58	2.73	1.96	1.86	0.53	0	68.24	WT	WT	
XELOX+Bevacizumab	2.96	2.61	3.08	2.92	1.89	1.85	-0.28	0	80.07	WT	NA	
XELOX+Bevacizumab	3.29	2.89	3.50	2.73	2.31	2.25	2.28	0	77.34	WT	MUT	
XELOX+Bevacizumab	3.14	2.71	3.13	2.72	1.91	1.79	-0.08	1	26.64	WT	MUT	
XELOX+Bevacizumab	3.31	2.66	3.43	2.38	2.23	2.08	1.07	0	75.76	WT	MUT	
XELOX+Bevacizumab	3.11	2.39	2.76	1.88	2.09	2.10	-1.41	0	77.11	WT	MUT	
XELOX+Bevacizumab	3.04	2.77	3.10	2.60	2.12	2.07	0.44	0	78.42	WT	NA	
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	72.28	WT	MUT	
XELOX+Bevacizumab	3.23	3.11	3.01	2.92	2.38	1.34	1.07	0	78.62	WT	NA	
XELOX+Bevacizumab	3.18	2.63	3.33	2.48	2.00	2.06	0.36	0	84.96	WT	WT	
XELOX+Bevacizumab	2.87	2.60	3.23	2.46	2.02	1.87	-0.47	0	60.65	WT	WT	
XELOX+Bevacizumab	3.06	2.79	3.05	2.19	2.05	2.33	0.11	0	59.99	WT	WT	
XELOX+Bevacizumab	3.03	2.42	3.37	2.48	2.13	2.12	0.22	0	76.58	WT	WT	
XELOX+Bevacizumab	2.93	2.50	2.95	1.81	1.88	2.04	-1.78	0	54.24	NA	NA	
XELOX+Bevacizumab	3.01	3.12	3.05	2.69	2.12	2.49	1.44	0	61.08	WT	MUT	
XELOX+Bevacizumab	3.21	2.80	2.80	2.50	2.05	2.39	0.39	0	78.52	WT	NA	
XELOX+Bevacizumab	3.21	2.86	3.31	2.78	2.59	2.60	2.85	0	84.93	MUT	NA	
XELOX+Bevacizumab	3.13	2.78	3.35	2.34	2.06	2.61	1.18	0	62.55	WT	WT	
XELOX+Bevacizumab	3.11	2.32	3.06	2.16	2.23	1.72	-0.96	0	83.15	MUT	NA	
XELOX+Bevacizumab	2.73	2.55	2.73	2.59	1.90	1.96	-1.45	1	64.23	WT	NA	
XELOX+Bevacizumab	2.89	2.33	2.82	2.22	1.84	1.76	-2.20	0	60.16	WT	NA	
XELOX+Bevacizumab	3.10	2.90	3.28	2.62	2.12	2.51	1.52	0	84.17	MUT	MUT	
XELOX+Bevacizumab	3.07	2.47	3.04	2.20	1.88	2.02	-1.07	0	60.19	WT	WT	
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	79.44	WT	MUT	
XELOX+Bevacizumab	2.96	2.65	2.96	2.33	2.04	2.10	-0.52	0	78.46	WT	MUT	
XELOX+Bevacizumab	3.18	2.76	3.38	2.09	1.94	2.41	0.47	0	82.56	WT	MUT	
XELOX+Bevacizumab	3.14	2.64	3.21	2.20	2.36	1.77	0.16	0	84.01	WT	NA	
XELOX+Bevacizumab	3.19	2.75	3.14	2.83	1.69	1.79	-0.24	0	86.93	WT	NA	
XELOX+Bevacizumab	3.30	2.72	3.15	2.36	2.01	2.58	0.89	0	62.72	MUT	WT	
XELOX+Bevacizumab	3.24	2.87	3.06	2.14	2.14	2.34	0.62	0	60.81	WT	WT	
XELOX+Bevacizumab	3.48	2.60	3.15	2.98	2.28	2.05	1.56	0	68.67	WT	WT	
XELOX+Bevacizumab	2.93	3.00	3.33	2.56	2.05	2.03	0.74	0	59.14	WT	NA	
XELOX+Bevacizumab	2.96	3.31	3.11	2.68	2.31	2.46	2.07	0	78.23	MUT	WT	
XELOX+Bevacizumab	2.74	2.88	2.66	2.64	2.12	2.62	0.25	0	62.36	WT	NA	
XELOX+Bevacizumab	2.45	2.61	2.88	2.47	1.87	1.68	-2.04	0	65.87	WT	NA	
XELOX+Bevacizumab	3.09	3.03	2.85	2.64	2.00	2.05	0.33	0	60.91	WT	NA	

XELOX+Bevacizumab	3.29	2.91	3.39	2.70	2.06	2.21	1.60	0	58.97	WT	MUT	
XELOX+Bevacizumab	2.95	2.67	3.46	2.70	1.97	1.92	0.34	0	64.95	WT	NA	
XELOX+Bevacizumab	3.26	3.04	3.36	2.60	2.38	3.14	3.31	1	27.5	MUT	WT	
XELOX+Bevacizumab	3.29	2.15	3.50	2.30	2.33	2.23	0.65	0	79.87	NA	NA	
XELOX+Bevacizumab	3.14	2.65	3.24	2.58	1.92	1.81	-0.13	1	52.53	MUT	NA	
XELOX+Bevacizumab	3.17	2.92	3.60	2.77	1.85	2.09	1.28	0	60.52	WT	NA	
XELOX+Bevacizumab	3.24	2.69	3.47	2.26	2.12	2.46	1.20	0	69.52	NA	WT	
XELOX+Bevacizumab	3.31	2.77	3.27	2.86	2.25	1.95	1.46	0	79.08	MUT	WT	
XELOX+Bevacizumab	3.16	2.87	3.40	2.74	1.72	1.75	0.20	0	74.94	WT	NA	
XELOX+Bevacizumab	3.14	2.63	3.32	2.41	1.96	1.98	0.04	0	84.14	WT	NA	
XELOX+Bevacizumab	3.02	2.66	3.10	2.19	2.29	2.51	0.62	0	82.83	WT	NA	
XELOX+Bevacizumab	3.45	2.90	3.47	2.88	1.96	1.97	1.63	0	67.98	WT	MUT	
XELOX+Bevacizumab	3.81	3.18	3.59	2.99	2.76	2.33	4.79	1	38.67	WT	WT	
XELOX+Bevacizumab	3.29	3.22	3.15	3.06	2.11	2.03	1.99	0	60.45	WT	NA	
XELOX+Bevacizumab	2.65	2.59	2.84	1.88	1.81	2.16	-2.08	0	83.38	WT	NA	
XELOX+Bevacizumab	3.59	2.81	3.26	2.82	1.88	1.83	0.96	0	75.79	WT	NA	
XELOX+Bevacizumab	3.04	2.77	3.19	2.42	2.27	2.04	0.61	0	60.58	WT	WT	
XELOX+Bevacizumab	3.05	2.61	3.14	2.15	2.08	2.14	-0.26	0	68.7	NA	WT	
XELOX+Bevacizumab	3.28	2.88	3.26	2.47	1.94	2.49	1.16	0	65.97	WT	MUT	
XELOX+Bevacizumab	3.31	2.69	3.09	2.48	2.09	2.39	0.85	0	78.19	WT	MUT	
XELOX+Bevacizumab	2.92	2.43	3.38	2.29	2.19	2.01	-0.13	1	8.87	WT	WT	
XELOX+Bevacizumab	3.25	2.67	3.50	2.31	1.98	2.12	0.60	0	59.63	WT	MUT	
XELOX+Bevacizumab	3.50	3.24	3.43	3.09	2.06	1.83	2.42	0	77.4	WT	MUT	
XELOX+Bevacizumab	3.02	2.89	3.36	2.47	1.89	2.23	0.57	0	65.84	WT	NA	
XELOX+Bevacizumab	2.94	2.67	3.30	2.55	2.14	2.12	0.47	0	77.7	WT	NA	
XELOX+Bevacizumab	3.01	2.63	3.24	2.92	2.19	2.03	0.84	0	61.9	WT	WT	
XELOX+Bevacizumab	2.43	2.47	3.09	2.53	1.88	1.59	-1.99	0	82.4	WT	MUT	
XELOX+Bevacizumab	3.16	3.05	3.34	2.90	2.23	2.11	2.00	0	79.9	WT	MUT	
XELOX+Bevacizumab	2.85	2.40	2.95	1.62	1.92	2.03	-2.19	0	87.89	WT	NA	
XELOX+Bevacizumab	3.36	2.92	3.13	2.52	2.03	2.76	1.70	0	63.51	WT	MUT	
XELOX+Bevacizumab	3.30	2.92	2.99	2.72	2.18	2.22	1.28	0	78.46	WT	MUT	
XELOX+Bevacizumab	2.90	2.37	2.94	1.54	1.86	2.30	-2.05	0	78.03	WT	NA	
XELOX+Bevacizumab	2.66	2.68	3.09	2.20	1.97	2.24	-0.80	0	84.96	WT	NA	
XELOX+Bevacizumab	3.06	2.92	3.22	2.57	1.64	2.45	0.36	0	79.7	WT	MUT	
XELOX+Bevacizumab	3.42	2.91	2.91	2.69	1.96	2.55	1.24	0	58.22	WT	MUT	
XELOX+Bevacizumab	3.44	3.05	3.40	2.94	1.99	2.29	2.27	0	73	WT	MUT	
XELOX+Bevacizumab	2.45	2.43	2.74	2.36	1.86	1.36	-3.05	0	82.56	WT	MUT	
XELOX+Bevacizumab	3.34	2.67	3.21	2.26	2.40	2.38	1.36	1	31.84	WT	MUT	
XELOX+Bevacizumab	2.47	2.32	2.98	2.63	1.90	1.70	-2.02	0	85.78	WT	NA	
XELOX+Bevacizumab	3.17	2.98	3.38	2.92	2.07	2.06	1.61	0	66.53	WT	WT	
XELOX+Bevacizumab	2.82	2.44	2.96	2.21	1.72	1.53	-2.45	0	83.55	WT	MUT	
XELOX+Bevacizumab	3.31	2.99	3.40	2.71	1.80	1.94	0.93	0	73.66	WT	MUT	
XELOX+Bevacizumab	3.01	2.59	3.19	2.51	1.92	1.98	-0.35	0	63.05	WT	NA	
XELOX+Bevacizumab	3.15	3.19	3.24	2.61	2.31	1.88	1.57	0	78.69	WT	WT	
XELOX+Bevacizumab	2.83	2.58	3.34	2.53	1.78	1.95	-0.66	0	71.92	WT	WT	
XELOX+Bevacizumab	3.13	2.87	3.34	2.63	2.18	2.08	1.24	0	78.92	WT	MUT	

XELOX+Bevacizumab	3.51	2.92	3.36	2.52	2.49	2.02	2.22	0	76.19	MUT	NA
XELOX+Bevacizumab	3.22	2.90	3.34	2.52	1.73	2.26	0.61	0	59.86	WT	MUT
XELOX+Bevacizumab	2.77	2.88	3.29	2.45	1.78	1.84	-0.59	0	60.78	WT	WT
XELOX+Bevacizumab	2.97	2.67	3.32	2.54	2.03	2.16	0.37	0	81.87	WT	NA
XELOX+Bevacizumab	2.91	3.04	3.32	2.27	1.81	2.52	0.55	0	78.85	MUT	NA
XELOX+Bevacizumab	3.02	2.76	3.22	2.48	1.91	1.61	-0.53	0	85.42	WT	NA
XELOX+Bevacizumab	2.81	2.91	3.13	2.61	1.94	2.61	0.72	0	80.59	WT	WT
XELOX+Bevacizumab	2.94	2.83	3.34	3.05	2.16	1.73	0.94	1	83.15	WT	MUT
XELOX+Bevacizumab	3.10	2.30	3.31	2.57	2.21	2.24	0.43	0	64.23	MUT	NA
XELOX+Bevacizumab	2.99	2.90	3.45	2.88	1.90	1.85	0.71	0	83.71	WT	WT
XELOX+Bevacizumab	3.31	2.89	3.21	2.73	1.88	2.63	1.52	0	67.81	WT	MUT
XELOX+Bevacizumab	3.24	2.91	3.05	2.73	1.92	2.00	0.53	0	82.99	WT	MUT

**Supplementary Table 13: Individual MAPK gene expression, MPAS and overall survival of patients with CRC in the adjuvant setting (AVANT).**